id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-293701-u4ntxo0y	Su, Shan	Learning from the past: development of safe and effective COVID-19 vaccines	2020-10-16		.txt	text/plain	8201	390	40	In this Perspective, we summarize examples of vaccine-associated disease enhancement in the history of developing vaccines against respiratory syncytial virus, dengue virus, SARS-CoV and Middle East respiratory syndrome coronavirus, which highlight the importance of a robust safety and efficacy profile, and present recommendations for preclinical and clinical evaluation of COVID-19 vaccine candidates as well as for vaccine design and optimization. One month later, five more candidates had also entered phase I clinical trials, and more than 100 COVID-19 vaccine candidates were in results, all of these vaccines induced antibodies against the spike protein (S protein) and the receptor-binding domain (RBD), including antibodies that neutralized pseudotyped and live SARS-CoV-2. We summarize examples of VADE in the history of the development of vaccines against respiratory syncytial virus (RSV), dengue virus (DENV), SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), each of which provides clues for safe COVID-19 vaccine development and highlights the need for rigorous preclinical and clinical safety testing.	./cache/cord-293701-u4ntxo0y.txt	./txt/cord-293701-u4ntxo0y.txt